PPCB Stock Overview
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Propanc Biopharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0028 |
52 Week High | US$0.70 |
52 Week Low | US$0.0023 |
Beta | 1.66 |
1 Month Change | -3.10% |
3 Month Change | -79.93% |
1 Year Change | -99.38% |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
PPCB | US Biotechs | US Market | |
---|---|---|---|
7D | -1.4% | -0.06% | 2.1% |
1Y | -99.4% | 9.8% | 30.4% |
Return vs Industry: PPCB underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: PPCB underperformed the US Market which returned 30.4% over the past year.
Price Volatility
PPCB volatility | |
---|---|
PPCB Average Weekly Movement | 29.4% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PPCB's share price has been volatile over the past 3 months.
Volatility Over Time: PPCB's weekly volatility has decreased from 53% to 29% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 2 | James Nathanielsz | https://www.propanc.com |
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells.
Propanc Biopharma, Inc. Fundamentals Summary
PPCB fundamental statistics | |
---|---|
Market cap | US$219.91k |
Earnings (TTM) | -US$2.73m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PPCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PPCB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$2.73m |
Earnings | -US$2.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.038 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -27.7% |
How did PPCB perform over the long term?
See historical performance and comparison